RG2 [D74] (ATCC® CRL-2433)

Organism: Rattus norvegicus, rat  /  Cell Type: Glioblastoma  /  Tissue: brain  /  Disease: differentiated malignant glioma

Organism Rattus norvegicus, rat
Tissue brain
Cell Type Glioblastoma
Product Format frozen
Morphology glial
Culture Properties adherent
Biosafety Level 1
Disease differentiated malignant glioma
Age fetus, 20 days gestation
Applications
This cell line may be used for both in vitro and in vivo studies of a rat brain tumor. It grows well in cell culture and provides a simple, reproducible glioma model when inoculated into the brains of syngeneic rats.The RG2 and F98 (ATCC CRL-2397) gliomas can be used as rat brain tumor models in experimental neuro-oncology.
Derivation
RG2 was submitted to the American Type Culture Collection in March, 1999 at passage 3 from a culture established from a tumor.
This tumor was produced by Drs. A. Koestner and W. Wechsler at The Ohio State University in 1971.
Tumorigenic Yes
Effects
Yes, in CD Fischer rats
Comments
This cell line has been designated RG2 or RG-2 (rat glioma 2) and it is the same as that called D74-RG2 or D74.

The transplantable tumor displays an infiltrative pattern of growth within the brain.

The RG2 cells are non-immunogenic in syngeneic Fischer rats despite intensive immunization.

RG2 was submitted to the American Type Culture Collection in March, 1999 at passage 3 from a culture established from a tumor.

Complete Growth Medium The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Subculturing Volumes used in this protocol are for 75 cm2 flask; proportionally reduce or increase amount of dissociation medium for culture vessels of other sizes.
  1. Remove and discard culture medium.
  2. Briefly rinse the cell layer with 0.25% (w/v) Trypsin-0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor.
  3. Add 2.0 to 3.0 mL of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
    Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.
  4. Add 6.0 to 8.0 mL of complete growth medium and aspirate cells by gently pipetting.
  5. Add appropriate aliquots of the cell suspension to new culture vessels.
  6. Incubate cultures at 37°C

Subculture Ratio: 1:4 to 1:8
Medium Renewal: Every 2 to 3 days.
Note: For more information on enzymatic dissociation and subculturing of cell lines consult Chapter 10 in Culture of Animal Cells, a manual of Basic Technique by R. Ian Freshney, 3rd edition, published by Alan R. Liss, N.Y., 1994.

Cryopreservation
Culture medium, 95%; DMSO, 5%
Culture Conditions
Temperature: 37°C
Name of Depositor RF Barth
Passage History
RG2 was submitted to the American Type Culture Collection in March, 1999 at passage 3 from a culture established from a tumor.
Year of Origin 1999
References

Ko L, et al. Morphological characterization of nitrosourea-induced glioma cell lines and clones. Acta Neuropathol. 51: 23-31, 1980. PubMed: 7435138

Tzeng JJ, et al. Adoptive immunotherapy of a rat glioma using lymphokine-activated killer cells and interleukin 2. Cancer Res. 50: 4338-4343, 1990. PubMed: 2364388

Tzeng JJ, et al. Phenotype and functional activity of tumor-infiltrating lymphocytes isolated from immunogenic and nonimmunogenic rat brain tumors. Cancer Res. 51: 2373-2378, 1991. PubMed: 2015600

Kobayashi N, et al. An improved rat brain-tumor model. J. Neurosurg. 53: 808-815, 1980. PubMed: 7003068

Barth RF. Rat brain tumor models in experimental neuro-oncology: the 9L, C6, T9, F98, RG2 (D74), RT-2 and CNS-1 gliomas. J. Neuro-Oncol. 36: 91-102, 1998. PubMed: 9525831

Swenberg JA, et al. The induction of tumors of the nervous system with intravenous methylnitrosourea. Lab. Invest. 26: 74-85, 1972. PubMed: 4333080

Swenberg JA, et al. Quantitative aspects of transplacental tumor induction with ethylnitrosourea in rats. Cancer Res. 32: 2656-2660, 1972. PubMed: 4345400

Aas AT, et al. The RG2 rat glioma model. J. Neuro-Oncol. 23: 175-183, 1995. PubMed: 7673979

Groothuis DR, et al. Permeability of different experimental brain tumor models to horseradish peroxidase. J. Neuropathol. Exp. Neurol. 41: 164-185, 1982. PubMed: 7062086

Groothuis DR, et al. Regional measurements of blood-to-tissue transport in experimental RG-2 rat gliomas. Cancer Res. 43: 3368-3373, 1983. PubMed: 6850641

Rapoport SI. Osmotic opening of the blood-brain barrier. Ann. Neurol. 24: 677-684, 1988. PubMed: 3059990

Ernestus RI, et al. Polyamine metabolism in experimental brain tumors of rat. J. Neurochem. 60: 417-422, 1993. PubMed: 8419528

Ceberg CP, et al. A comparative study on the pharmacokinetics and biodistribution of boronated porphyrin (BOPP) and sulfhydryl boron hydride (BSH) in the RG2 rat glioma model. J. Neurosurg. 83: 86-92, 1995. PubMed: 7782856

Ceberg CP, et al. Enhanced boron uptake in RG 2 rat gliomas by electropermeabilization in vivo--a new possibility in boron neutron capture therapy. Anticancer Drugs 5: 463-466, 1994. PubMed: 7949252

Molnar P, et al. The effects of dexamethasone on experimental brain tumors: I. Transcapillary transport and blood flow in RG-2 rat gliomas. J. Neuro-Oncol. 25: 19-28, 1995. PubMed: 8523086

Devineni D, et al. Tissue distribution of methotrexate following administration as a solution and as a magnetic microsphere conjugate in rats bearing brain tumors. J. Neuro-Oncol. 24: 143-152, 1995. PubMed: 7562001

Devineni D, et al. In vivo microdialysis to characterize drug transport in brain tumors: analysis of methotrexate uptake in rat glioma-2 (RG-2)-bearing rats. Cancer Chemother Pharmacol. 38: 499-507, 1996. PubMed: 8823490

Gallo JM, et al. Targeting anticancer drugs to the brain: II. Physiological pharmacokinetic model of oxantrazole following intraarterial administration to rat glioma-2 (RG-2) bearing rats. J. Pharmacokinet. Biopharm. 21: 575-592, 1993. PubMed: 8145132

Tjuvajev J, et al. RG-2 glioma growth attenuation and severe brain edema caused by local production of interleukin-2 and interferon-gamma. Cancer Res. 55: 1902-1910, 1995. PubMed: 7728757

Basic Documentation
References

Ko L, et al. Morphological characterization of nitrosourea-induced glioma cell lines and clones. Acta Neuropathol. 51: 23-31, 1980. PubMed: 7435138

Tzeng JJ, et al. Adoptive immunotherapy of a rat glioma using lymphokine-activated killer cells and interleukin 2. Cancer Res. 50: 4338-4343, 1990. PubMed: 2364388

Tzeng JJ, et al. Phenotype and functional activity of tumor-infiltrating lymphocytes isolated from immunogenic and nonimmunogenic rat brain tumors. Cancer Res. 51: 2373-2378, 1991. PubMed: 2015600

Kobayashi N, et al. An improved rat brain-tumor model. J. Neurosurg. 53: 808-815, 1980. PubMed: 7003068

Barth RF. Rat brain tumor models in experimental neuro-oncology: the 9L, C6, T9, F98, RG2 (D74), RT-2 and CNS-1 gliomas. J. Neuro-Oncol. 36: 91-102, 1998. PubMed: 9525831

Swenberg JA, et al. The induction of tumors of the nervous system with intravenous methylnitrosourea. Lab. Invest. 26: 74-85, 1972. PubMed: 4333080

Swenberg JA, et al. Quantitative aspects of transplacental tumor induction with ethylnitrosourea in rats. Cancer Res. 32: 2656-2660, 1972. PubMed: 4345400

Aas AT, et al. The RG2 rat glioma model. J. Neuro-Oncol. 23: 175-183, 1995. PubMed: 7673979

Groothuis DR, et al. Permeability of different experimental brain tumor models to horseradish peroxidase. J. Neuropathol. Exp. Neurol. 41: 164-185, 1982. PubMed: 7062086

Groothuis DR, et al. Regional measurements of blood-to-tissue transport in experimental RG-2 rat gliomas. Cancer Res. 43: 3368-3373, 1983. PubMed: 6850641

Rapoport SI. Osmotic opening of the blood-brain barrier. Ann. Neurol. 24: 677-684, 1988. PubMed: 3059990

Ernestus RI, et al. Polyamine metabolism in experimental brain tumors of rat. J. Neurochem. 60: 417-422, 1993. PubMed: 8419528

Ceberg CP, et al. A comparative study on the pharmacokinetics and biodistribution of boronated porphyrin (BOPP) and sulfhydryl boron hydride (BSH) in the RG2 rat glioma model. J. Neurosurg. 83: 86-92, 1995. PubMed: 7782856

Ceberg CP, et al. Enhanced boron uptake in RG 2 rat gliomas by electropermeabilization in vivo--a new possibility in boron neutron capture therapy. Anticancer Drugs 5: 463-466, 1994. PubMed: 7949252

Molnar P, et al. The effects of dexamethasone on experimental brain tumors: I. Transcapillary transport and blood flow in RG-2 rat gliomas. J. Neuro-Oncol. 25: 19-28, 1995. PubMed: 8523086

Devineni D, et al. Tissue distribution of methotrexate following administration as a solution and as a magnetic microsphere conjugate in rats bearing brain tumors. J. Neuro-Oncol. 24: 143-152, 1995. PubMed: 7562001

Devineni D, et al. In vivo microdialysis to characterize drug transport in brain tumors: analysis of methotrexate uptake in rat glioma-2 (RG-2)-bearing rats. Cancer Chemother Pharmacol. 38: 499-507, 1996. PubMed: 8823490

Gallo JM, et al. Targeting anticancer drugs to the brain: II. Physiological pharmacokinetic model of oxantrazole following intraarterial administration to rat glioma-2 (RG-2) bearing rats. J. Pharmacokinet. Biopharm. 21: 575-592, 1993. PubMed: 8145132

Tjuvajev J, et al. RG-2 glioma growth attenuation and severe brain edema caused by local production of interleukin-2 and interferon-gamma. Cancer Res. 55: 1902-1910, 1995. PubMed: 7728757